Cytomegalovirus seropositivity is independently associated with cardiovascular disease in non-dialysis dependent chronic kidney disease.
Cardiovascular disease (CVD) is the leading cause of early death in patients with chronic kidney disease (CKD). Previous work has described an association between CMV seropositivity and cardiovascular disease amongst patients with dialysis dependent end stage renal disease. Whether CMV seropositivity is associated with cardiovascular disease in non-dialysis dependent CKD has not been established. Investigate whether past CMV infection is associated with prevalent cardiovascular disease in patients with non-dialysis dependent CKD. A retrospective observational study using the Renal Impairment in Secondary Care (RIISC) cohort, a study evaluating bio-clinical determinants of outcomes in patients with progressive CKD. We assayed cryopreserved serum samples collected at inception for anti-CMV IgG antibodies from 764 patients with stages 2 to 5 CKD (pre-dialysis) and investigated its relationship with prevalent cardiovascular disease. Median eGFR was 24 ml/min/1.73m2 (IQR 19-32). Sixty-eight percent of patients were CMV seropositive. CMV seropositivity was associated with older age, non-Caucasian ethnicity, diabetes and higher social deprivation index score. On univariable analysis, CMV seropositivity correlated with higher systolic blood pressure (p = 0.044), prevalent cardiovascular disease (p < 0.001), ischaemic heart disease (p < 0.001) and cerebrovascular disease (p = 0.022). On multivariable analysis, CMV seropositive patients nearly twice as likely to have cardiovascular disease compared to seronegative patients (OR = 1.998, CI 1.231-3.242, p = 0.005). In patients with non-dialysis CKD, CMV seropositivity is independently associated with a higher prevalence of cardiovascular disease.